PRASUGREL (prasugrel) by Accord Biopharma is p2y 12 class of adp receptors on platelets. Approved for thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome, non-st-elevation myocardial infarction (nstemi) ( ), rate of thrombotic cv events (including stent thrombosis) in patients with acute coronary syndrome (acs) and 1 more indications. First approved in 2018.
Drug data last refreshed 19h ago
P2Y 12 class of ADP receptors on platelets.
Worked on PRASUGREL at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Disparities in the Proportion of Ticagrelor and Prasugrel-eligible Patients with Acute Coronary Syndrome in a Real-world Registry
PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction
Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients
Prasugrel in Severe COVID-19 Pneumonia
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)